New Horizon Aircraft (HOVR) Q1 2027 Earnings Call Transcript

Horizon Aircraft reported a Q1 FY2027 net loss of C$4.1 million (C$0.06 per share), versus C$10.9 million (C$0.29 per share) a year earlier; the improvement included a C$3.8 million non-cash gain on warrant liabilities. Cash exceeded C$70 million as of August 31, 2026, which management expects to fund at least 24 months, while operating cash use rose to C$7.2 million from C$2.4 million and R&D expense increased to C$7.4 million from C$2.7 million. Management targets completing the full-scale Cavorite X7 demonstrator around the end of Q1 2027 and aims for certification in early 2030; signed LOIs indicate potential sales of more than C$1 billion for up to 200 aircraft, but are not binding orders. Management also cautioned that incidents during testing at other major aerospace OEMs could affect Horizon.

Analysis

HOVR’s key valuation test is no longer whether it can attract operator interest, but whether it can turn engineering spend into credible flight data without forcing dilutive financing. The LOIs should be treated as a pipeline, not backlog: conversion depends on a flying aircraft and subsequent progress, while the stated early-2030 certification goal leaves years before ordinary civil revenue. Consequently, near-term headlines around demonstrator completion can move the stock, but they do not yet resolve the long-duration funding and execution risk.

The contrarian angle is that the hybrid design may avoid some charging-infrastructure constraints, but the proposed all-weather/known-icing differentiation is not bankable until testing and certification substantiate it. Those capabilities could improve utilization and operator economics if proven; they also add validation and certification work that could lengthen the path. A sector-wide safety incident could pressure HOVR despite its different architecture, as management itself acknowledges.

BETA’s flight-control involvement may reduce HOVR’s need to build a critical system internally, but the call provides no contract economics or evidence of material revenue for BETA. Do not extrapolate a supplier relationship into an earnings catalyst for BETA, or treat HOVR as a direct substitute for shorter-range Joby or Archer missions. Immediate upside is milestone optionality; over 1–3 months, verify demonstrator progress and funding; over 6–18 months, flight-test results and LOI conversion matter more than announced potential sales. Falsifiers include a missed build/test schedule, adverse flight results, rising cash use that prompts discounted equity issuance, or certification slippage.

Key Decisions for Investors

• HOVR: Keep on a high-risk milestone watchlist rather than buying on LOI headline value. Reassess after the demonstrator is completed and ground testing begins; require observable progress toward piloted flight testing before treating the thesis as de-risked.
• If taking exposure, use a small, staged long only around verifiable build and test milestones; avoid sizing against the stated LOI totals. The principal downside is schedule slippage combined with higher burn and dilution; the upside is technical validation that improves the credibility of customer interest.
• Track quarterly operating cash use, cash balance, ATM activity, and reimbursed/non-dilutive funding. A sustained burn increase or material equity issuance before flight-test progress would weaken the case; management’s runway assertion is not a substitute for monitoring those figures.
• No compelling trade in ACHR, JOBY, BETA, or HON from this call alone. Treat any major eVTOL testing incident as a potential sector-wide risk catalyst, while requiring evidence before attributing HOVR’s progress or economics to its named suppliers or competitors.